title: Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy.
abstract: Purpose. Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is indicated for high-grade nonmuscle-invasive bladder cancer (NMIBC). The efficacy of BCG in patients with a history of previous pelvic radiotherapy (RT) may be diminished. We evaluated the outcomes of radical cystectomy for BCG-treated recurrent bladder cancer in patients with a history of RT for prostate cancer (PC). Methods. A retrospective chart review was performed to identify patients with primary NMIBC. We compared the outcomes of three groups of patients who underwent radical cystectomy for BCG-refractory NMIBC: those with a history of RT for PC, those who previously underwent radical prostatectomy (RP), and a cohort without PC or RT exposure. Results. From 1996 to 2008, 53 patients underwent radical cystectomy for recurrent NMIBC despite BCG. Those with previous pelvic RT were more likely to have a higher pathologic stage and decreased recurrence-free survival compared to the groups without prior RT exposure. Conclusion. Response rates for intravesical BCG therapy may be impaired in those with prior prostate radiotherapy. Patients with a history of RT who undergo radical cystectomy after failed BCG are more likely to be pathologically upstaged and have decreased recurrence-free survival. Earlier consideration of radical cystectomy may be warranted for those with NMIBC who previously received RT for PC.
authors: Department of Urology, Loyola University Medical Center, Room 261, Maywood, IL 60153, USA.
authors: Manoj V
authors: MV
authors: Rao
authors: Marcus L
authors: ML
authors: Quek
authors: Gautam
authors: G
authors: Jayram
authors: Chandy
authors: C
authors: Ellimoottil
authors: Timothy
authors: T
authors: Sondej
authors: Cory M
authors: CM
authors: Hugen
authors: Robert C
authors: RC
authors: Flanigan
authors: Gary D
authors: GD
authors: Steinberg
references: Urology. 2012 Dec;80(6):1236-42
references: 23206767
references: World J Urol. 2002 Aug;20(3):151-7
references: 12196898
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: BJU Int. 2013 Feb;111(2):213-20
references: 22928860
references: J Urol. 1988 Jun;139(6):1202-4
references: 3373587
references: J Urol. 2008 Jan;179(1):91-5; discussion 95
references: 17997457
references: Urology. 2003 Feb;61(2):342-7; discussion 347
references: 12597943
references: Eur Urol. 2010 Jun;57(6):1058-63
references: 20022162
references: J Urol. 2007 Dec;178(6):2314-30
references: 17993339
references: J Urol. 2010 Dec;184(6):2264-9
references: 20952024
references: J Urol. 2006 Jun;175(6):2063-6
references: 16697804
references: Urol Oncol. 2013 Aug;31(6):857-61
references: 21868262